Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co., Ltd.

LaserView is involved in eye surgery services, self-described as a reference in this field.

LaserView

AIER Eye Hospital is a global eye care provider with a network of hospitals and centers across multiple countries, offering ophthalmology services and medical education.

AIER Eye Hospital

Assil Gaur Eye Institute provides LASIK surgery, cataract surgery, glaucoma care, and various aesthetic eye treatments. It specializes in patient-focused eye care and surgical services.

Assil Gaur Eye Institute

Santen Pharmaceutical Co., Ltd specializes in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people worldwide.

Metric
Company Name	Santen Pharmaceutical Co., Ltd.	LaserView	AIER Eye Hospital	Assil Gaur Eye Institute
Symbol	4.54K
MSH ID	COM:SANTEN	BR:COM:LASERVIEW	COM:AIERCHINA:EN	COM:ASSILEYE
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Medical Services	Eye Care and Ophthalmology	Medical Services
Country	JP	BR	CN	US
Stage			Series A
Employee Count	3.74K
Website	santen.com	laserview.com.br	en.aierchina.com	assileye.com
LinkedIn
Founders

Metric
Market Cap	4.34B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital		1.45M

Metric
Revenue	2.01B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.09B
EBITDA	467.39M
Operating Income	346.16M
Net Income	177.68M
EPS	0.48
Diluted EPS	0.48
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.61
Operating Profit Margin	0.16
EBITDA Margin	0.23
Net Profit Margin	0.09
Return on Equity	0.09
Return on Assets	0.06
Return on Capital Employed	0.14

COM:SANTEN

Santen Pharmaceutical Co., Ltd

Last Close

1,670.50

25/11 06:45

Market Cap

650.87B

Beta: -

Volume Today

1.70M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	19.65
P/B Ratio	1.69
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.20
EV Multiple	11.60

Metric
Days Sales Outstanding	115.31
Days Payables Outstanding	137.47
Days Inventory Outstanding	146.05
Operating Cycle	246.43
Cash Conversion Cycle	165.05
Asset Turnover	0.71

Metric
Operating Cash Flow	484.52M
Free Cash Flow	413.25M
Cash Flow to Debt	2.52
Operating Cash Flow/Sales	0.27
Free Cash Flow Yield	0.06

Metric
Cash & Equivalents	630.80M
Accounts Receivable	122.61M
Inventory	288.02M
Goodwill
Debt to Capitalization	0.10
Debt to Assets
Current Ratio	2.66
Quick Ratio	2.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.09
SG&A to Revenue	0.33